PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?

Overview of attention for article published in Frontiers in Neuroscience, January 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 3 news outlets
blogs: 1 blog

twitter: 4 X users

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 58 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 195,716 followers.

RT @FrontNeurosci: New Research: PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?: PDE10A, a phosphodiesterase…

04 Feb 2021

Reply Repost Favourite

RT @FrontNeurosci: New Research: PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?: PDE10A, a phosphodiesterase…

03 Feb 2021

Reply Repost Favourite

RT @FrontNeurosci: New Research: PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?: PDE10A, a phosphodiesterase…

03 Feb 2021

Reply Repost Favourite

New Research: PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?: PDE10A, a phosphodiesterase that inactivates both cAMP and cGMP, is a unique signaling molecule in being highly and nearly exclusively expressed in… https://t.co/gf

03 Feb 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.